Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
The demonstrated benefits for high-risk individuals with atherosclerotic CVD, heart failure (HF) or chronic kidney disease (CKD) afforded by the glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodiumglucose cotransporter-2 inhibitors (SGLT2i) provide important progress in treatment aimed at reducing the progression and burden of diabetes and its complications
These risks have not been established for retatrutide in humans and should be regarded as hypothetical at this stage, pending further trial data
Mounjaro may be preferable for patients who require effective treatment with established safety profiles, particularly those with Type 2 diabetes who need both glycaemic control and weight management
Retatrutide is being studied in people with obesity, overweight and type 2 diabetes, but it is not currently approved as a diabetes or weight loss treatment in the UK
